title: Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards?
authors.affiliation: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Irene
authors.initials: I
authors.lastname: Guijarro-Muñoz
authors.affiliation: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Emily B
authors.initials: EB
authors.lastname: Roarty
authors.affiliation: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.|Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: John V
authors.initials: JV
authors.lastname: Heymach
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
chemical_list: D000970:Antineoplastic Agents; D000068258:Bevacizumab
references.citation: Nat Biotechnol. 2007 Aug;25(8):911-20
references.pmid: 17664940
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4743-50
references.pmid: 17909199
references.citation: Clin Cancer Res. 2010 Aug 1;16(15):3887-900
references.pmid: 20554752
references.citation: Lancet. 2014 Aug 23;384(9944):665-73
references.pmid: 24933332
references.citation: J Clin Invest. 2011 Apr;121(4):1313-28
references.pmid: 21436589
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3499-506
references.pmid: 22949147
references.citation: Lancet Oncol. 2013 Jan;14(1):29-37
references.pmid: 23168366
references.citation: J Clin Oncol. 2013 Nov 1;31(31):3926-34
references.pmid: 24101054
references.citation: Lancet Oncol. 2014 Feb;15(2):143-55
references.pmid: 24411639